Fesoterodine fumarate

CAS No. 286930-03-8

Fesoterodine fumarate( PF-00695838 fumarate )

Catalog No. M13874 CAS No. 286930-03-8

Fesoterodine (PF-00695838) is a competitive muscarinic receptor antagonist with muscle relaxant and urinary antispasmodic properties.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 49 In Stock
2MG 29 In Stock
5MG 43 In Stock
10MG 65 In Stock
25MG 102 In Stock
50MG 137 In Stock
100MG 211 In Stock
200MG Get Quote In Stock
500MG 409 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Fesoterodine fumarate
  • Note
    Research use only, not for human use.
  • Brief Description
    Fesoterodine (PF-00695838) is a competitive muscarinic receptor antagonist with muscle relaxant and urinary antispasmodic properties.
  • Description
    Fesoterodine (PF-00695838) is a competitive muscarinic receptor antagonist with muscle relaxant and urinary antispasmodic properties; binds and inhibits muscarinic receptors on the bladder detrusor muscle, prevents bladder contractions or spasms caused by acetylcholine.Other Indication Approved(In Vitro):FFesoterodine Fumarate decreases micturition frequency, urgency severity and urgency incontinence episodes and increases the volume voided with each micturition.After oral administration, Fesoterodine Fumarate is rapidly and extensively hydrolysed in plasma by nonspecific esterases to Desfesoterodine (5-hydroxymethyl tolterodine; SPM 7605; HY-76569; an active metabolite of Fesoterodine).(In Vivo):Fesoterodine Fumarate (0.01-1 mg/kg; IV) reduces the micturition pressure and increases bladder capacity and ICIs (intercontraction intervas) at the lowest dose tested of 0.01 mg/kg.
  • In Vitro
    FFesoterodine Fumarate decreases micturition frequency, urgency severity and urgency incontinence episodes and increases the volume voided with each micturition.After oral administration, Fesoterodine Fumarate is rapidly and extensively hydrolysed in plasma by nonspecific esterases to Desfesoterodine (5-hydroxymethyl tolterodine; SPM 7605; HY-76569; an active metabolite of Fesoterodine).
  • In Vivo
    Fesoterodine Fumarate (0.01-1 mg/kg; IV) reduces the micturition pressure and increases bladder capacity and ICIs (intercontraction intervas) at the lowest dose tested of 0.01 mg/kg. Animal Model:Bladders from female Sprague-Dawley rats (225-275 g)Dosage:0.01, 0.1 and 1 mg/kg Administration:IV Result:Reduced the micturition pressure and increased bladder capacity and ICIs at the lowest dose tested of 0.01 mg/kg.
  • Synonyms
    PF-00695838 fumarate
  • Pathway
    GPCR/G Protein
  • Target
    mAChR
  • Recptor
    mAChR
  • Research Area
    Other Indications
  • Indication
    Other Disease

Chemical Information

  • CAS Number
    286930-03-8
  • Formula Weight
    527.658
  • Molecular Formula
    C30H41NO7
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 93 mg/mL (176.3 mM); Ethanol: 93 mg/mL (176.3 mM); Water: 92 mg/mL (174.4 mM) ( < 1 mg/ml refers to the product slightly soluble or insoluble )
  • SMILES
    CC(C)C(=O)OC1=C(C=C(C=C1)CO)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.C(=C/C(=O)O)\C(=O)O
  • Chemical Name
    [2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate fumarate

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Ney P, et al. BJU Int. 2008 Apr;101(8):1036-42. 2. Michel MC. Expert Opin Pharmacother. 2008 Jul;9(10):1787-96. 3. Chapple CR, et al. BJU Int. 2008 Nov;102(9):1128-32.
molnova catalog
related products
  • Glycopyrrolate

    A muscarinic anticholinergic that blocks muscarinic receptors, thus inhibiting cholinergic transmission.

  • Revefenacin

    A novel potent, long-acting, lung-selective inhaled muscarinic antagonist that has high affinity at M3 receptor.

  • Glycopyrronium bromi...

    Glycopyrronium bromide (CHF 5259) is a peripherally-acting quaternary ammonium antimuscarinic agent with little or no central nervous system activity.